Work

Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Early Relapsed/Refractory Multiple Myeloma

Year: 2022

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood-2022-169838

Authors: Anupama Kumar, Aaron S Rosenberg, Michelle Padilla, Nina Shah, Lindsey Sirianni, Lin Liu, Yuwei Cheng, Emily Pittman, Dimitrios Tzachanis, Sarah Larson, Carolyn Mulroney, Edward D. Ball, Caitlin Costello

Institutions: University of California San Diego, University of California Davis Medical Center, University of California, Davis, University of California, San Francisco, University of California, Los Angeles, Moores Cancer Center

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4310125500

FWCI:

Cites:

Cited by:

Related to: 10